$IDYA
IDEAYA Biosciences, Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020024653 Filed on May 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.450M $2.780M $2.100M
YoY Change 64.29% 78.21% 135.96%
% of Gross Profit
Research & Development $9.026M $8.540M $7.996M
YoY Change 12.88% 12.66% 53.77%
% of Gross Profit
Depreciation & Amortization $336.0K $330.0K $293.0K
YoY Change 14.68% 22.22% 54.21%
% of Gross Profit
Operating Expenses $12.48M $11.32M $10.09M
YoY Change 23.62% 23.94% 65.83%
Operating Profit -$12.48M -$10.09M
YoY Change 23.62%
Interest Expense $440.0K $540.0K $530.0K
YoY Change -16.98% -5.26% 89.29%
% of Operating Profit
Other Income/Expense, Net $435.0K $0.00 $525.0K
YoY Change -17.14% 650.0%
Pretax Income -$12.04M -$10.78M -$9.570M
YoY Change 25.81% 25.93% 66.72%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.04M -$10.78M -$9.569M
YoY Change 25.85% 25.92% 66.79%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$594.6K -$531.0K -$491.3K
COMMON SHARES
Basic Shares Outstanding 20.33M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $87.90M $99.00M $79.00M
YoY Change 11.27%
Cash & Equivalents $35.46M $34.07M $35.30M
Short-Term Investments $52.40M $64.90M $43.70M
Other Short-Term Assets $1.600M $2.700M $900.0K
YoY Change 77.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $89.50M $101.7M $79.90M
YoY Change 12.02% 12.12%
LONG-TERM ASSETS
Property, Plant & Equipment $4.337M $4.642M $10.90M
YoY Change -60.21% -9.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.000M $1.500M
YoY Change
Other Assets $16.00K $16.00K $1.900M
YoY Change -99.16% -65.22%
Total Long-Term Assets $12.29M $11.35M $12.80M
YoY Change -3.98% 93.17%
TOTAL ASSETS
Total Short-Term Assets $89.50M $101.7M $79.90M
Total Long-Term Assets $12.29M $11.35M $12.80M
Total Assets $101.8M $113.0M $92.70M
YoY Change 9.81% 17.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $684.0K $709.0K $1.700M
YoY Change -59.76% -49.96%
Accrued Expenses $5.429M $5.023M $4.000M
YoY Change 35.73% 40.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.346M $6.940M $5.800M
YoY Change 26.66% 28.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $21.00K $34.00K $6.600M
YoY Change -99.68% -69.91%
Total Long-Term Liabilities $21.00K $34.00K $6.600M
YoY Change -99.68% -69.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.346M $6.940M $5.800M
Total Long-Term Liabilities $21.00K $34.00K $6.600M
Total Liabilities $12.69M $12.60M $12.30M
YoY Change 3.15% 77.53%
SHAREHOLDERS EQUITY
Retained Earnings -$92.49M
YoY Change 83.09%
Common Stock $192.8M
YoY Change 11959.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $89.10M $100.4M -$58.06M
YoY Change
Total Liabilities & Shareholders Equity $101.8M $113.0M $92.70M
YoY Change 9.82% 17.05%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q1
OPERATING ACTIVITIES
Net Income -$12.04M -$10.78M -$9.569M
YoY Change 25.85% 25.92% 66.79%
Depreciation, Depletion And Amortization $336.0K $330.0K $293.0K
YoY Change 14.68% 22.22% 54.21%
Cash From Operating Activities -$9.545M -$8.700M -$9.785M
YoY Change -2.45% 16.31% 76.94%
INVESTING ACTIVITIES
Capital Expenditures -$210.0K $606.0K
YoY Change -32.26% -375.45%
Acquisitions
YoY Change
Other Investing Activities $10.91M $4.110M $26.01M
YoY Change -58.05% -40.35% -143.15%
Cash From Investing Activities $10.91M $3.890M $25.41M
YoY Change -57.08% -40.88% -142.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 34.00K 40.00K -826.0K
YoY Change -104.12% -150.0% -100.78%
NET CHANGE
Cash From Operating Activities -9.545M -8.700M -9.785M
Cash From Investing Activities 10.91M 3.890M 25.41M
Cash From Financing Activities 34.00K 40.00K -826.0K
Net Change In Cash 1.395M -4.770M 14.80M
YoY Change -90.57% 386.73% -62.44%
FREE CASH FLOW
Cash From Operating Activities -$9.545M -$8.700M -$9.785M
Capital Expenditures -$210.0K $606.0K
Free Cash Flow -$8.490M -$10.39M
YoY Change 18.41% 95.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
3040000
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1526000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4337000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4828000
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16000
CY2020Q1 us-gaap Assets
Assets
101791000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
684000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5429000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1145000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
63000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6940000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1176000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
57000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7346000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5321000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5627000
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34000
CY2020Q1 us-gaap Liabilities
Liabilities
12688000
CY2019Q4 us-gaap Liabilities
Liabilities
12601000
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
192824000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20339461
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
383000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
37000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7996000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
242000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
384000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-727000
CY2020Q1 idya Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-275000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20347539
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-9569000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-65000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
39000
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20347539
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20339461
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9026000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3452000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2098000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
12478000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
10094000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12478000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10094000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
435000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
525000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12043000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12108000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9530000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.69
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20250549
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1101107
CY2020Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
0
CY2020Q1 idya Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Shares
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfShares
16000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
758000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-65000
CY2019Q1 idya Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Shares
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfShares
32000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
39000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-58062000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-12043000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-9569000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
336000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
293000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-5000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
236000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
758000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
383000
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
CY2019Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2020Q1 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
2000
CY2019Q1 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
1000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1097000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
151000
CY2020Q1 idya Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-229000
CY2019Q1 idya Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-256000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-36000
CY2019Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2020Q1 idya Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
22159000
CY2019Q1 idya Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
39340000
CY2019Q1 idya Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
6000000
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2019Q1 idya Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-278000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9545000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9785000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
606000
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
11253000
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
19326000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10906000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25408000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2019Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
827000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-826000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1395000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14797000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34173000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20611000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35568000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35408000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35302000
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
106000
CY2019Q1 us-gaap Restricted Cash
RestrictedCash
106000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
21000
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
24000
CY2019Q1 idya Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
375000
CY2020Q1 idya Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
16000
CY2019Q1 idya Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
74000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
33000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
481000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, stock-based compensation, and income taxes. Actual results could differ from those estimates. </p>
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all the Company&#8217;s cash is held by one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company&#8217;s investment policy addresses credit ratings, diversification, and maturity dates. The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities. </p>
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
55441000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
70000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
70000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
55441000
CY2020Q1 idya Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
90900000
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0975
CY2020Q1 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
90902000
CY2020Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
90902000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
66350000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
69000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
66415000
CY2019Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
100358000
CY2019Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
100423000
CY2020Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2019Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7186000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7158000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2849000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2516000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1234000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1733000
CY2020Q1 idya Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3517000
CY2019Q4 idya Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2787000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
621000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
457000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
CY2020Q1 idya Number Of Common Stock Voting Rights Held Per Share
NumberOfCommonStockVotingRightsHeldPerShare
1
CY2020Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2019 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4202972
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3194078
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
758000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
383000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.03
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.50
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5900000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M9D
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M21D
CY2020Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
2811
CY2019Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.849
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.797
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.867
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.822
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.006
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8700000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.023
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.015
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.025
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020Q1 idya Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
20341247
CY2019Q1 idya Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
1337851
CY2020Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
90698
CY2019Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
236744
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2723038
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15391009

Files In Submission

Name View Source Status
0001564590-20-024653-index-headers.html Edgar Link pending
0001564590-20-024653-index.html Edgar Link pending
0001564590-20-024653.txt Edgar Link pending
0001564590-20-024653-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
idya-10q_20200331.htm Edgar Link pending
idya-20200331.xml Edgar Link completed
idya-20200331.xsd Edgar Link pending
idya-20200331_cal.xml Edgar Link unprocessable
idya-20200331_def.xml Edgar Link unprocessable
idya-20200331_lab.xml Edgar Link unprocessable
idya-20200331_pre.xml Edgar Link unprocessable
idya-ex102_336.htm Edgar Link pending
idya-ex103_337.htm Edgar Link pending
idya-ex104_335.htm Edgar Link pending
idya-ex311_8.htm Edgar Link pending
idya-ex312_9.htm Edgar Link pending
idya-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending